Posters

Following the landmark approval of imatinib 20 years ago, over 70 kinase inhibitors are now transforming the clinical care of multiple malignancies and a handful of other disorders.

Therapies targeting RAS, a small GTPase that is frequently altered in cancer, are explored in this poster.

The complement pathway plays key roles in host defence, but its excessive activation or dysregulation can lead to a variety of disorders. This poster overviews strategies to therapeutically intervene in the pathway and the new generation of complement inhibitors that are now in the clinic.